Clinical Value of Monitoring BMD in Patients Treated With Bisphosphonates for Osteoporosis
Open Access
- 1 October 2009
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 24 (10) , 1643-1646
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial dataBMJ, 2009
- Mixed models showed no need for initial response monitoring after starting antihypertensive therapyJournal of Clinical Epidemiology, 2009
- Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to Vertebral and Nonvertebral Fractures From 2 US Claims DatabasesMayo Clinic Proceedings, 2006
- Monitoring Osteoporosis Therapy: Bone Mineral Density, Bone Turnover Markers, or Both?The American Journal of Medicine, 2006
- Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention TrialOsteoporosis International, 2004
- Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With RisedronateJournal of Clinical Densitometry, 2004
- Regression to the Mean: What Does it Mean?Journal of Clinical Densitometry, 2001
- Study Subjects and Ordinary PatientsOsteoporosis International, 2000
- Bone Matters: Are Density Increases Necessary to Reduce Fracture Risk?Journal of Bone and Mineral Research, 2000
- Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fracturesBMJ, 1996